Skip to main content
NCBI home page
Cytotechnology logoLink to Cytotechnology
. 1998 Nov;28(1-3):53–64. doi: 10.1023/A:1008013211222

New adenovirus vectors for protein production and gene transfer

Bernard Massie 1,3,✉, Dick D Mosser 1, Maria Koutroumanis 1, Isabelle Vitté-mony 1, Linda Lamoureux 1, France Couture 1, Luc Paquet 1, Claire Guilbault 1,7, Julie Dionne 1, Dounia Chahla 1, Pierre Jolicoeur 1, Yves Langelier 7
PMCID: PMC3449830  PMID: 19003407

Abstract

Based on two new adenovirus expression cassettes, we have constructed a series of Ad transfer vectors for the overexpression of one or two genes either in a dicistronic configuration or with separate expression cassettes. Inclusion of the green or blue fluorescent protein in the vectors accelerates the generation of adenovirus recombinants and facilitates the functional characterization of genes both in vitro and in vivo by allowing easy quantification of gene transfer and expression. With our optimized tetracycline-regulated promoter (TR5) we have generated recombinant adenoviruses expressing proteins, that are either cytotoxic or which interfere with adenovirus replication, at levels of 10–15% of total cell protein. Proteins that are not cytotoxic can be produced at levels greater than 20% of total cell protein. As well, these levels of protein production can be achieved with or without adenovirus replication. This yield is similar to what can be obtained with our optimized human cytomegalovirus-immediate early promoter-enhancer (CMV5) for constitutive protein expression in non-complementing cell lines. Using the green fluorescent protein as a reporter, we have shown that a pAdCMV5-derived adenovirus vector expresses about 6-fold more protein in complementing 293 cells and about 12-fold more in non- complementing HeLa cells than an adenovirus vector containing the standard cytomegalovirus promoter. Moreover, a red-shifted variant of green fluorescent protein incorporated in one series of vectors was 12-fold more fluorescent than the S65T mutant, making the detection of the reporter protein possible at much lower levels of expression.

Keywords: adenoviral recombinant, functional genomics, gene therapy, green fluorescent protein, inducible gene expression, protein production

Full Text

The Full Text of this article is available as a PDF (191.3 KB).

References

  1. Acsadi G, Jani A, Massie B, Simoneau M, Holland P, Blaschuk K, Karpati G. A differential efficiency of adenovirus-mediated in vivogene transfer into skeletal muscle cells of different maturity. Hum Mol Genetic. 1994;3:579–584. doi: 10.1093/hmg/3.4.579. [DOI] [PubMed] [Google Scholar]
  2. Acsadi G, Massie B, Jani A. Adenovirus-mediated gene transfer into striated muscles. J Mol Med. 1995;73:165–180. doi: 10.1007/BF00188137. [DOI] [PubMed] [Google Scholar]
  3. Berkner KL. Development of adenovirus vector for the expression of heterologous genes. BioTechniques. 1988;6:616–629. [PubMed] [Google Scholar]
  4. Berkner KL. Expression of heterologous sequences in adenoviral vectors. Curr Top Microbiol Immunol. 1992;158:39–66. doi: 10.1007/978-3-642-75608-5_3. [DOI] [PubMed] [Google Scholar]
  5. Dayan A, Bertrand R, Beauchemin M, Chahla D, Mamo A, Filion M, Skup D, Massie B, Jolivet J. Cloning and characterization of the human 5,10-methenyltetrahydrofolate synthetaseencoding cDNA. Gene. 1995;165:307–311. doi: 10.1016/0378-1119(95)00321-V. [DOI] [PubMed] [Google Scholar]
  6. Garnier A, Côté J, Nadeau I, Kamen A, Massie B. Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells. Cytotechnology. 1994;15:145–155. doi: 10.1007/BF00762389. [DOI] [PubMed] [Google Scholar]
  7. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992;89:5547–5551. doi: 10.1073/pnas.89.12.5547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science. 1995;268:1766–1769. doi: 10.1126/science.7792603. [DOI] [PubMed] [Google Scholar]
  9. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines. In: Ellis RW, editor. Vaccines: New Approaches to Immunological Problems. Boston, Mass: Butterworth-Heinemann; 1992. pp. 363–390. [DOI] [PubMed] [Google Scholar]
  10. Heim R, Cubitt AB, Tsien RY. Improved green fluorescence. Nature. 1995;373:663–664. doi: 10.1038/373663b0. [DOI] [PubMed] [Google Scholar]
  11. Hu SX, Ji W, Zhou Y, Logothetis C, Xu HJ. Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. Cancer Res. 1997;57:3339–3343. [PubMed] [Google Scholar]
  12. Jani A, Lochmüller H, Acsadi G, Simoneau M, Huard J, Garnier A, Karpati G, Massie B. Generation, validation and large scale production of adenoviral recombinants with large inserts such as 6.3 kb human dystrophin cDNA. J Virolog Meth. 1997;64:111–124. doi: 10.1016/S0166-0934(96)02138-6. [DOI] [PubMed] [Google Scholar]
  13. Lamarche N, Massie B, Richer M, Paradis H, Langelier Y. High level expression in 293 cells of the herpes simplex virus type 2 ribonucleotide reductase subunit 2 using an adenovirus vector. J Gen Virol. 1990;71:1785–1792. doi: 10.1099/0022-1317-71-8-1785. [DOI] [PubMed] [Google Scholar]
  14. Massie B (1998) BMAdE1, a new complementing cell line for the large scale production of E1-deleted Adenovirus (Ad) vectors devoid of RCA (replication competent Ad). filed on 26/04/96; Issued 09/98).
  15. Massie B, Couture F, Lamoureux L, Mosser DD, Guilbault C, Jolicoeur P, Belanger F, Langelier Y. Inducible over-expression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. J Virol. 1998;72:2289–2296. doi: 10.1128/jvi.72.3.2289-2296.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Massie B, Dionne J, Lamarche N, Fleurent J, Langelier Y. Improved adenovirus vector provides herpes simplex virus ribonucleotide reductase R1 and R2 subunits very efficiently. Bio/Technology. 1995;13:602–608. doi: 10.1038/nbt0695-602. [DOI] [PubMed] [Google Scholar]
  17. McKinnon RD, Bacchetti S, Graham FL. Tn5 mutagenensis of the transforming genes of human adenovirus type 5. Gene. 1982;19:33–42. doi: 10.1016/0378-1119(82)90186-X. [DOI] [PubMed] [Google Scholar]
  18. Mittereder N, March K, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996;70:7498–7509. doi: 10.1128/jvi.70.11.7498-7509.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mosser DD, Caron AW, Bourget L, Jolicoeur P, Massie B. Use of a dicistronic expression cassette encoding the green-fluorescent protein for the screening and selection of cells expressing inducible gene products. Biotechniques. 1997;22:150–161. doi: 10.2144/97221rr02. [DOI] [PubMed] [Google Scholar]
  20. Mosser DD, Caron AW, Bourget L, Denis-Larose C, Massie B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol Cell Biol. 1997;17:5317–5327. doi: 10.1128/mcb.17.9.5317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Palm GJ, Zdanov A, Gaitanaris GA, Stauber R, Pavlakis GN, Wlodawer A. The structural basis for spectral variations in green fluorescent protein. Nat Struct Biol. 1997;4:361–365. doi: 10.1038/nsb0597-361. [DOI] [PubMed] [Google Scholar]
  22. Rao L, Modha D, White E. The E1B 19K protein associates with lamins in vivoand its proper localization is reuired for inhibition of apoptosis. Oncogene. 1997;15:1587–1597. doi: 10.1038/sj.onc.1201323. [DOI] [PubMed] [Google Scholar]
  23. Stauber RH, Ilorie K, Carney P, Hudson EA, Tarasova NI, Galtanaris GA, Pavlakis GN. Development and applications of enhanced green fluorescent protein mutants. BioTechniques. 1998;24:462–471. doi: 10.2144/98243rr01. [DOI] [PubMed] [Google Scholar]
  24. Stratford-Perricaudet L. D., Perricaudet M. Gene therapy: the advent of adenovirus. In: Wolff J. A., editor. Gene Therapeutics: Methods and Applications of Direct Gene Transfer. Cambridge, Mass: Birkhauser Boston; 1994. pp. 344–362. [Google Scholar]
  25. Teodoro JG, Branton PE. Regulation of apoptosis by viral gene products. J Virol. 1997;71:1739–1746. doi: 10.1128/jvi.71.3.1739-1746.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Trapnell BC, Gorzilia M. Gene therapy using adenoviral vectors. Curr Opinion in Biotech. 1994;5:617–625. doi: 10.1016/0958-1669(94)90084-1. [DOI] [PubMed] [Google Scholar]
  27. White E, Cipriani R, Sabbatini P, Denton A. Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. Virol. 1991;65:2968–2978. doi: 10.1128/jvi.65.6.2968-2978.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Xu ZZ, Krougliak V, Prevec L, Graham FL, Both GW. Investigation of promoter function and animal cells infected with human recombinant adenoviruses expressing rotavirus antigen VP7sc. J Gen Virol. 1995;76:1971–1980. doi: 10.1099/0022-1317-76-8-1971. [DOI] [PubMed] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES